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Plasma Cell Disorders
Introduction
Proteasome inhibition is a backbone for multiple myeloma
treatment.1 While control of myeloma can be achieved with
first- and second-line therapy utilizing proteasome inhibitors
and immunomodulating agents (IMIDs), most myeloma
patients die from myeloma that has become refractory to
antimyeloma drugs. Partial response rates achieved by next
generation drugs like carfilzomib or pomalidomide are only in
the 20% range in proteasome inhibitor-resistant myeloma.2-4
Overcoming proteasome inhibitor resistance is a central
unmet clinical need for myeloma patients.5
Myeloma cells synthesize large amounts of immunoglobu-
lin protein, accompanied by constitutive activation of the
unfolded protein response (UPR),6 a homeostatic mechanism
that limits protein biosynthesis, facilitates protein folding and
increases proteolytic destruction of misfolded protein by the
proteasome.7 They, therefore, critically rely on proteasomal
disposal and undergo apoptosis via a terminal unfolded pro-
tein response when proteasomal proteolysis is disturbed.8,9
The proteasome carries three proteolytically active sites
(β1, β2 and β5), which differ in their substrate preferences.10
These subunits of the so-called constitutive proteasome can
be replaced by respective immunoproteasome subunits β1i,
β2i and β5i in some cell types, including myeloma,11 which
results in a total of six different proteolytic enzymes with dif-
ferent substrate preferences in the 20S proteasome core parti-
cle. The two approved proteasome-inhibiting drugs, borte-
zomib and carfilzomib, by design target the β5 subunit of the
constitutive proteasome and the immunoproteasome, which
mediate the rate-limiting proteolytic proteasome activity.1,12
Several β5-targeted next generation proteasome inhibiting
drugs like delanzomib13 (CEP-18770), ixazomib14 (MLN-2238),
and oprozomib15 (ONX-0912) are under development.
Mutations in the bortezomib binding pocket16,17 have been
suggested to provide bortezomib resistance in myeloma,
based on in vitro studies, but have not been confirmed in vivo.18
Recent data suggest that changes in the activation state of the
unfolded protein response allow myeloma cells to resist β5-
targeted proteasome inhibitors: bortezomib resistance can be
achieved by elimination of IRE-1a,19 an endonuclease that
controls the activation state of the transcription factor XBP-1,
which is the key regulator of the UPR and plasma cell matu-
ration at the same time. Consequently, bortezomib-resistance
©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.109421
The online version of this article has a Supplementary Appendix.
Manuscript received on April 23, 2014. Manuscript accepted on June 5, 2015.
Correspondence: christoph.driessen@kssg.ch
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but
not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of
the unfolded protein response, and up-regulate β2 proteasome activity. To improve proteasome inhibition in borte-
zomib-resistant myeloma and to achieve more efficient UPR activation, we have developed LU-102, a selective
inhibitor of the β2 proteasome activity. LU-102 inhibited the β2 activity in intact myeloma cells at low micromolar
concentrations without relevant co-inhibition of β1 and β5 proteasome subunits. In protea-some inhibitor-resis-
tant myeloma cells, significantly more potent proteasome inhibition was achieved by bortezomib or carfilzomib
in combination with LU-102, compared to bortezomib/carfilzomib alone, resulting in highly synergistic cytotoxic
activity of the drug combination via endoplasmatic reticulum stress-induced apoptosis. Combining
bortezomib/carfilzomib with LU-102 significantly prolonged proteasome inhibition and increased activation of
the unfolded protein response and IRE1-a activity. IRE1-a has recently been shown to control myeloma cell dif-
ferentiation and bortezomib sensitivity (Leung-Hagesteijn, Cancer Cell 24:3, 289-304). Thus, β2-selective protea-
some inhibition by LU-102 in combination with bortezomib or carfilzomib re-sults in synergistic proteasome inhi-
bition, activation of the unfolded protein response, and cytotoxicity, and overcomes bortezomib/carfilzomib
resistance in myeloma cells in vitro. 
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ABSTRACT
by IRE-1a knockdown is characterized by decreased acti-
vation of the UPR and a less mature phenotype with a lack
of fully developed ER. Likewise, myeloma cells adapted to
bortezomib treatment in vitro (bortezomib-adapted cells)
have a reduced rate of protein biosynthesis and a low acti-
vation state of the UPR.20 Together, these data support a
“low-IRE-1-a/XBP-1-model” of bortezomib resistance, the
validity of which is supported by the identification of
XBP1-negative, immature myeloma cell populations accu-
mulating in bortezomib-resistant patients.19
The degree of cytotoxicity of β5-targeting proteasome
inhibitors against myeloma cell lines correlates with their
degree of additional inhibition of the β2- or β1 subunits.21
Conversely, bortezomib-adapted myeloma cells increase
β2 proteasome activity, which may allow the bortezomib-
mediated proteasome inhibition to be by-passed.20 We
hypothesized that additional inhibition of β2 proteasome
activity in bortezomib-resistant myeloma cells would
increase the degree of proteasome inhibition achieved by
bortezomib alone, and re-sensitize them for bortezomib
treatment via IRE-1a activation and induction of a termi-
nal UPR. With this aim in view, we have developed the
first synthetic proteasome inhibitor to inhibit the β2 activ-
ity,21 and have improved its cell permeability and potency,
yielding the compound LU-102,22 which sensitizes
RPMI8226 cells to bortezomib and carfilzomib-induced
cytotoxicity.  We now address the potential of LU-102 to
overcome bortezomib/carfilzomib-resistance.
Methods
Cells and Inhibitors 
Human myeloma cell lines RPMI8226, LP-1, AMO-1, U266
(obtained from ATCC), MM1S and MM1R (obtained from ATCC)
were maintained in 10% FCS-supplemented RPMI-1640 medium
with gentamycin. AMO-abtz/acfz cells were adapted to protea-
some inhibitor-containing culture conditions as described.20 The
proteasome inhibitors bortezomib, carfilzomib and LU-10222 were
synthesized at the Leiden Institute of Chemistry. The selective
inhibitors NC-001 (inhibiting β1/β1i) and NC-005 (β5/β5i) have
been described by Britton et al.21 
MTT assay, western blot, antibodies
Cell viability was determined using the MTT [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium] method using commercial kits (details
in the Online Supplementary Appendix). SDS-PAGE and western
blot were performed as described (for antibodies see Online
Supplementary Appendix).23
Determination of proteasome activity by active-site
labeling
The proteasome-specific activity-based probes MV-151, BOD-
IPY-NC-005-vs and BODIPY(RED)-NC-001 were used and meas-
ured as described;23-25 the synthesis of BODIPY(RED)-NC-001 will
be described elsewhere. Both the constitutive and the immuno-
proteasome subunits are labeled by MV-151 in intact cells,26 and
resolved after cell lysis by SDS-PAGE.
Patients’ samples
Patients’ samples were obtained after written informed consent
and approval by the independent ethics review board, in accor-
dance with ICH-GCP and local regulations. Malignant plasma cells
were retrieved from peripheral blood or bone marrow of patients
with multiple myeloma or plasma cell leukemia, and enriched by
Ficoll density centrifugation or by CD138 magnetic sorting to a
purity of more than 80%, if necessary. 
Animal experiments
MM1.S cells were subcutaneously injected in SCID mice and
treated with LU-102 (30 mg/kg) via intraperitoneal, and carfil-
zomib via intravenous injection twice weekly (Figure 6). Tumors
were measured twice weekly and mice were euthanized when
tumors reached 3000 mm3. (See Online Supplementary Appendix for
details.)
Statistical analysis            
Unless stated otherwise, one representative experiment out of
at least three independent experiments is shown. For MTT assays
mean values from quadruplicate samples are represented and syn-
ergism was calculated using R as described by Chou et al.27 A com-
bination Index (CI) <0.8 indicates synergism, >1 indicates antago-
nism. Statistical significance was calculated using Student’s t-test.  
Results
Selectivity of proteasome inhibition by LU-102 in 
myeloma cells
To compare target inhibition and specificity of LU-102
with the approved proteasome-inhibiting drugs in viable
myeloma cells, we performed activity-based proteasome
labeling experiments with the cell permeable proteasome
probe MV151 in RPMI8226 cells (Figure 1A). Bortezomib
and carfilzomib resulted in a significant decrease in β5/β5i
proteasome activity starting in the 0.03-0.1 μM concentra-
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Table 1. Patients’ characteristics.
ID #Prior Refract. Refract. Extramed. Primary Second. LU-102 Bortezomib Carfilzomib
lines of  to last to next manifest. PCL PCL sensitive sensitive sensitive
therapy bortezomib bortezomib in vitro in vitro in vitro
MM1 7 Yes Yes No No No No Not known Not known
MM2 1 Yes N/A Yes No No No No No
MM3 1 No No No Yes N/A Yes Not known Not known
MM4 4 Yes N/A Yes No Yes No No No
MM5 0 No No Yes Yes N/A Yes No Yes
MM6 7 Yes No No No No Yes No Yes
Clinical characteristics of patients from which primary myeloma/plasma cell leukemia samples were derived.  PCL: plasma cell leukemia. Cells were considered sensitive (+) for
treatment with the individual proteasome inhibitors in vitro, when more than 50% cytotoxicity was observed during continuous incubation with LU-102 3 μM: bortezomib 10 nM,
carfilzomib 5 nM. 
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tion range while bortezomib provided also inhibition of
β1/β1i activity. Interestingly, in contrast to bortezomib, at
higher concentrations (>0.1 μM) carfilzomib resulted in
additional concentration-dependent inhibition of β2/β2i
activity. In contrast to bortezomib and carfilzomib, LU-
102 resulted in selective and potent inhibition of β2/β2i
proteasome subunits.  Compared to these two, LU-102
was less active, so that 0.3-1 μM LU-102 was required for
measurable proteasome inhibition. 
To confirm selectivity of β2/β2i inhibition, we used
advanced affinity-based probes for selective visualization of
active β1 and β1i or the β5 and β5i subunits24 (Figure 1B).
Affinity labeling with MV-151 in conjunction with LU-102
showed the expected loss of β2-type of activity signals
without affecting β1- and β5-type of activities, while LU-
102 had no influence on the intensity of β5/β5i and β1/β1i-
selective labeling. Thus, we can exclude quantitatively rele-
vant co-inhibition of β1, β1i, β5 and β5i proteasome activity
when myeloma cells are exposed to 3.3 μM LU-102. 
Selective inhibition of β2/β2i in RPMI8226 and AMO-1
myeloma cell lines resulted in accumulation of polyubi-
quitinated (polyUb) protein, suggesting a quantitative role
for the β2/β2i proteasome activity in protein breakdown
in myeloma cells. The activity and selectivity of LU-102
was confirmed in a panel of myeloma cell lines (data not
shown).
Cytotoxic effect of β2/β2i proteasome inhibition 
To assess the cytotoxic effect of β2 proteasome subunit
inhibition on myeloma cells, we incubated myeloma cell
lines and primary cells with the respective inhibitors. At
the β2/β2i selective concentration of 3.3 μM or less, 
LU-102 induced moderate cytotoxicity in myeloma cell
lines and in 3 of 6 primary myeloma cell samples, while
the viability of PBMC was unaffected (Table 1 and Figure
2A). The β2/β2i-selective proteasome inhibition was
unable to induce cytotoxicity in carfilzomib-adapted
(AMO-acfz) or bortezomib-adapted (AMO-abtz) cells,
indicating that inhibition of the trypsin-type proteasome
activity alone is not sufficient to overcome bortezomib or
carfilzomib resistance (Figure 2B and Online Supplementary
Figures S1 and S2).  
Combination treatment with LU-102 overcomes 
proteasome inhibitor resistance 
The excellent selectivity of LU-102 for the β2/β2i protea-
some activity suggested to combine LU-102 with β5-target-
ed proteasome inhibitors to increase their therapeutic
potency (Figure 3A, left panels, and Online Supplementary
Figures S1 and S2). The combination of bortezomib or carfil-
zomib with LU-102 showed strong synergistic cytotoxicity
(CI between 0.129 and 0.048 for bortezomib or carfilzomib,
respectively; values less than 1 indicate synergism) in borte-
zomib-resistant AMO-abtz cells, while the respective
monotherapies had no or a considerably weaker, cytotoxic
effect. Likewise, carfilzomib-resistant cells (AMO-acfz)
showed highly synergistic cyto-toxicity when either borte-
zomib or carfilzomib was combined with LU-102 (CI 0.002
each), while the individual drugs lacked relevant cytotoxic
monoactivity in this setting. Similar results were obtained
with bortezomib- or carfilzomib-adapted versions of the
myeloma cell line LP-1 (data not shown). 
Because interactions of myeloma cells with bone mar-
row stroma provide resistance against proteasome
inhibitors,28 we co-cultured AMO-1 cells with the human
HS5 bone marrow stroma cell line and assessed the effects
of proteasome inhibition on myeloma cell viability (Figure
3A, middle panels). As expected, co-culture of myeloma
cells with HS5 cells resulted in significantly reduced sensi-
tivity against bortezomib or carfilzomib. The combination
of bortezomib/carfilzomib with LU-102 was sufficient to
overcome this stroma-mediated resistance against the two
approved proteasome inhibitors. To confirm that pro-
teotoxic stress was the major mechanism for this synergis-
tic cytotoxicity, we inhibited protein biosynthesis of
myeloma cells by cycloheximide exposure prior to chal-
lenging them with proteasome inhibitors (Figure 3A, right
panels). The combination treatment of LU-102 with either
carfilzomib or bortezomib resulted in less than 10% viable
RPMI8226 cells, which increased to 42% (bortezomib)
and 47% (carfilzomib) in the presence of cycloheximide,
indicating that reduced protein biosynthesis can partly res-
cue myeloma cells from the synergistic cytotoxicity that is
induced by the combined treatment with LU-102 and
bortezomib or carfilzomib.
Combination treatment with LU-102 overcomes 
proteasome inhibitor resistance in primary myeloma
cell samples
LU-102 showed highly synergistic cytotoxicity with
bortezomib also in all bortezomib-insensitive, malignant
primary plasma cell samples tested (CI <0.001, 0.132,
0.008, 0.09 for patients MM2, MM4, MM5, MM6) (Table
1 and Figure 3B), in contrast to PBMC. Likewise, synergis-
tic cytotoxicity of LU-102 with carfilzomib was observed
in the same samples, however, with weaker combination
indices (CI 0.391 for MM5 and 0.244 for MM6). This cor-
responded with the finding that MM5 and MM6 were still
carfilzomib-sensitive in vitro and the fact that all patients
were carfilzomib-naïve. By contrast, there was no such
synergy in PBMC with BTZ (CI 0.86±0.38) and a border-
line synergistic effect if any with CFZ (CI 0.78±0.18).
Importantly, the difference in CI between primary tumor
cell samples and PBMC was statistically significant for
CFZ and BTZ (P=0.01 and P<0.001) demonstrating superi-
or synergy in tumor cells versus PBMC. We conclude that
LU-102 in combination with bortezomib or carfilzomib
overcomes acquired bortezomib or carfilzomib resistance
of primary myeloma cells in vitro. 
Molecular activity of LU-102 in combination with
bortezomib/carfilzomib
To visualize to what extent the combination of LU-102
with bortezomib or carfilzomib would improve the
degree of proteasome inhibition in bortezomib/carfil-
zomib-resistant cells, we performed affinity labeling
experiments with MV-151 in the AMO-abtz /AMO-acfz
myeloma cells (Figure 4, upper panel). In the clinic, the
pharmacodynamic conditions during i.v. application of
carfilzomib are characterized by a rapid decline of carfil-
zomib plasma concentrations from 10 μM peak levels
directly after the i.v. push, to 2 nM after 60 min, so that
100 nM levels are reached at the 30 min time point.29 To
mimic these conditions, we exposed RPMI8226 cells to
the respective proteasome inhibitors for a 1 h pulse, fol-
lowed by removal of proteasome inhibitors. AMO-abtz
and AMO-acfz cells showed higher base-line proteasome
activities, and in particular, an increased β2/β2i activity
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Figure 1. (A). Selectivity of proteasome inhibition in intact myeloma cells RPMI8226 or AMO-1 myeloma cells were incubated with the cell-
permeable, proteasome specific, fluorogenic activity-based affinity probe MV151 in the presence or absence of the proteasome inhibitors indi-
cated. Cell lysates were resolved by SDS-PAGE. Specific fluorescence signals for the respective proteasome activities were visualized by fluo-
rescence scanning (upper part of the gels) and resolved quantitatively for the respective activities (β1, β2, β5) in the bar graphs relative to
control signals without proteasome inhibitor. Western blot for β-actin and polyubiquitinated protein served as loading control and to visualize
the accumulation of proteasome substrates upon inhibition of the β2-like activity. (B) Selectivity of LU-102 in myeloma cells  RPMI 8226
myeloma cells were incubated with the pan-reactive proteasome activity-specific affinity probe  MV151 in the presence or absence of the sub-
unit-selective inhibitors indicated (LU-102  3.3 μM, NC-001 and NC-005 5 μM). This was compared to cells labeled with the β5/β5i-selective
activity probe MVB125 and to a β1/β1i-selective labeling achieved by combining the probe EV-031 with pre-incubation with NC-005. Active
proteasome subunits were visualized as before. 
A
B
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compared to AMO-1, consistent with similar observations
made earlier in AMO-abtz cells20 (Figure 4A). We observed
complete or near-complete inhibition of proteasome
polypeptides when bortezomib or carfilzomib were com-
bined with LU-102 in AMO-1 cells, while some residual
active proteasome polypeptide could still be visualized in
bortezomib/carfilzomib-adapted cells under these condi-
tions. However, since base-line proteasome activity
detected was much higher in the adapted cells, compared
to the AMO-1 parental cells, the relative fraction inhibited
by the drug in both cell types was very similar, consistent
with unaffected interaction between bortezomib/carfil-
zomib and their target in adapted cells. Importantly, the
levels of total residual proteasome activity detected in pro-
teasome inhibitor resistant cells after treatment with
carfilzomib or bortezomib alone were consistently higher
compared to cells exposed to carfilzomib/bortezomib
combined with LU-102. Thus the combination of LU-102
with β5-targeted proteasome inhibitors results in superior
proteasome inhibition in bortezomib/carfilzomib-resis-
tant myeloma cells. 
We next assessed whether this would translate into
increased activation of the unfolded protein response and
consecutive apoptosis. RPMI8226 cells were exposed to
the respective proteasome inhibitors for a 1 h pulse, fol-
lowed by washing and a chase period of 4-16 h without
proteasome inhibitors, before the expression of proteins
indicating UPR activation and UPR-mediated apoptosis
was analyzed (Figure 4B). The combination of LU-102
with either bortezomib or carfilzomib resulted in upregu-
lation of pIRE-1a, ATF4, and CHOP expression, compared
to samples treated with the individual proteasome
inhibitors under the same conditions. This indicated supe-
rior triggering of the major molecular regulator of borte-
zomib-sensitivity (IRE-1a), alongside with the activation
of a “terminal” UPR with consecutive ER stress-induced
apoptosis by ATF4.7 Consistent with this, we observed
synergistic activation of caspases 9, 3 and 7 by borte-
zomib/carfilzomib in combination with LU-102, which
translated into apoptosis, as shown by expression of
cleaved poly(ADP-ribose) polymerase (PARP). This was
accompanied by superior activation of the MAPK path-
way (p-MEK, p-ERK, p-p38, p-JNK), and increased expres-
sion of p53, p27, p-STAT3 and p-cJUN that are all involved
Figure 2. (A). Single agent cytotoxici-
ty of LU-102 against myeloma cells.
The standard myeloma cell lines indi-
cated, as well as primary myeloma
cells (MM1-MM6, see Table 1) along-
side with PBMC from 2 healthy
donors, were incubated with the indi-
cated concentrations of LU-102,
carfilzomib or bortezomib for 48 h,
and cell viability was assessed by
MTT test. (B). Cytotoxicity of LU-102
in bortezomib/carfilzomib-resistant
myeloma cells. The bortezomib-resis-
tant AMO-abtz and the carfilzomib-
resistant AMO-acfz, were incubated
with the indicated concentrations of
LU-102, carfilzomib or bortezomib for
48 h as above, and cell viability was
assessed by MTT test.
A
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Figure 3. Effect of the combination of carfilzomib/bortezomib with LU-102 on the viability of bortezomib/carfilzomib resistant myeloma cells
(A) AMO-abtz and AMO-acfz (left panels) and AMO-1 cells cultured in the presence/absence of the human bone marrow stromal cell line HS5
(middle panels) were incubated with carfilzomib/bortezomib (CFZ/BTZ) and/or LU-102 (LU), followed by assessment of cell viability by MTT
test relative to untreated control cells. Right panel: RPMI8226  were cultured in the presence of bortezomib or carfilzomib with/without LU102
(1 μM) for 24 h, with/without treatment with cycloheximide (CHX, 2 μg/ml) for 4 h prior to incubation with proteasome inhibitors. The calcu-
lated combination indices (CI) for the respective combinations are indicated above the bar graphs. The following concentrations of inhibitors
were used: AMO-acfz: BTZ and CFZ: 33 nM, LU-102: 3 μM; all other cell lines: BTZ and CFZ: 10 nM, LU-102: 1 μM). (B) Primary malignant plas-
ma cells with bortezomib resistance (MM 2, 4, 5, 6, as characterized in Table 1) were assessed for cytotoxicity by MTT test after incubation
with the respective proteasome inhibitors alone or in combination (BTZ 10 nM, CFZ 5nM, LU-102 1 μM. For MM4, 20 nM BTZ was used). The
calculated combination indices (CI) for the respective combinations are indicated on top of the bar graphs. Control PBMC represent mean val-
ues from 7 healthy donors under the same conditions, statistical difference of the CI between PBMC versus primary malignant cells is indicat-
ed as *P=0.01, **P<0.001.
A
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Figure 4. (A) Effect of the combination of carfilzomib/bortezomib with LU-102 on proteasome activity in bortezomib/carfilzomib resistant
myeloma cells. AMO-1 myeloma cells as well as AMO-1 derived subclones selected to grow in the continued presence of bortezomib or carfil-
zomib (AMO-abtz, AMO-acfz, respectively) were pulse treated with proteasome inhibitors alone or in combination (BTZ and CFZ 100 nM each,
LU-102 3 μM, 1h) and active proteasome polypeptides in intact cells were visualized after affinity labeling with MV-151, cell lysis and SDS-
PAGE, using a fluorescence scanner. (B) Effect of the combination of bortezomib/carfilzomib with LU-102 on UPR-triggered apoptosis
RPMI8226 cells were pulse-treated with bortezomib or carfilzomib (BTZ , CFZ,100 nM) in the presence or absence of LU-102 (3 μM) for 1 h,
followed by washing and continued cell culture in the absence of proteasome inhibitors for 16 h. The expression of proteins indicative for acti-
vation of the unfolded protein response (BIP, CHOP, p-IRE1a, ATF4), of proteins involved in mediating the UPR-triggered apoptotic signal 
(p-MEK, p-ERK, p-p38, p-JNK, p53, p27, p-STAT3, p-c-JUN) as well as proteins indicating apoptosis (caspases 3, 7, 9, PARPp85) was analyzed
by western blot, relative to controls without proteasome inhibition. GAPDH and actin served as a protein loading control. 
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in apoptotic signaling triggered by the terminal UPR.30 The
apoptotic nature of cell death was demonstrated directly
via assessment of changes in mitochondrial membrane
potential and 7-AAD/Annexin V staining (Online
Supplementary Figures S1 and S2). In conclusion, additive
inhibition of the β2 proteasome subunit significantly
increases proteasome inhibition, activation of the UPR,
apoptotic signaling, and the induction of apoptosis in
bortezomib or carfilzomib-treated myeloma cells.    
Effect of LU-102 on the duration of proteasome 
inhibition achieved by bortezomib or carfilzomib
Superior activity of carfilzomib against myeloma cells
and bortezomib-insensitive tumor cells has been attrib-
uted to a longer duration of proteasome inhibition after
carfilzomib treatment, compared to bortezomib,12 based
on the irreversible nature of binding of carfilzomib. We
compared the impact of LU-102 on the duration of protea-
some inhibition, the recovery of proteasome function and
the accumulation of polyUb protein and its subsequent
recovery in myeloma cells treated with carfilzomib or
bortezomib (Figure 5). Pulse-treatment of RPMI 8226 cells
with bortezomib/carfilzomib (100 nM) or LU-102 
(3 μM) alone for 1 h resulted in inhibition of the individ-
ual active proteasome polypeptides. Combination treat-
ments of bortezomib/carfilzomib with LU-102 resulted in
true additive proteasome inhibition. The different
amounts of polyUb protein were consistent with this pat-
tern of inhibition. After 4 h of chase, the pattern of pro-
teasome inhibition had not changed, in agreement with
the slow off rate of bortezomib, and polyUb protein accu-
mulated in bortezomib or carfilzomib treated samples.
After 16 h, similar degrees of recovery of proteasome
activity were observed in bortezomib and carfilzomib-
treated myeloma cells, while poorer recovery of protea-
some activity was observed in cells treated with the com-
bination of LU-102 with either of the two approved pro-
teasome inhibitors. Importantly, polyUb protein was still
present in sizable amounts 16 h and up to 24 h after treat-
ment with LU-102 in combination with bortezomib or
carfilzomib, while it had cleared almost to background
levels in samples treated with bortezomib or carfilzomib
alone. Near-complete or complete proteasome recovery
after bortezomib or carfilzomib treatment was observed
LU-102 overcomes bortezomib and carfilzomib resistance 
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Figure 5. Effect of pulse treatment with carfil-
zomib/bortezomib with or without LU-102 on
proteasome activity and polyUb protein. (A)
RPMI8226 cells were exposed to carfilzomib
(CFZ) or bortezomib (BTZ, 100 nM each), with
or without LU-102 (LU, 3 μM) for 1 h. Following
consecutive removal of the proteasome
inhibitors by washing, cells were either imme-
diately analyzed (0 h), or cultured in the
absence of proteasome inhibitors for up to 72
h. Analysis of proteasome activity (activity-
based affinity labeling in intact cells with MV-
151, upper parts of the gel panels), protein
load (β-actin, western blot, middle part gel
panel) and polyubiquitinated protein (polyUb,
western blot, bottom parts gel panel) was per-
formed at the indicated chase times after
removal of proteasome inhibitors. Bar graphs
above the gel panels visualize the relative
amounts of β2(i) versus β5(i)/β1(i) protea-
some activity, as retrieved by quantitative fluo-
rescence scanning from the respective gels
below. (B) Cell viability of samples analyzed in
(A), as determined by MTT assay. Error bars
represent standard deviation between 3 indi-
vidual samples. 
A
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after 48 h, but was not observed even 72 h after exposure
to carfilzomib or bortezomib in combination with LU-
102. At the 48 h and the 72 h time points, respectively,
82% and 63% of cells treated with LU-102 in combina-
tion with bortezomib/carfilzomib were viable (Figure 5B)
compared to 100% in the cells treated without LU-102, so
that this difference could account only in part for the lack
of full proteasome recovery. Similar data were obtained
using AMO-1 cells (data not shown). The data demonstrate
that treatment of myeloma cells with LU-102 in combina-
tion with either bortezomib or carfilzomib prolongs the
duration of proteasome inhibition, which results in pro-
longed intracellular accumulation of proteasome sub-
strate protein in myeloma cells. 
LU 102 improves the antimyleoma activity of 
carfilzomib in vivo
MM1S cells were selected for in vivo testing as they have
only moderate sensitivity for carfilzomib/bortezomib
treatment (compare Figure 2B), and injected into SCID
mice. After subcutaneous tumor inoculation, mice were
treated with carfilzomib at a schedule providing 80% pro-
teasome inhibition in vivo (carfilzomib 2 mg/kg on a week-
ly day 1, 4 schedule for 8 weeks29). The LU-102 dose 30
mg/kg was co-administered with carfilzomib as indicated.
The dose was extrapolated from in vitro activity of LU-102
and inhibited more than 70% of the trypsin-like protea-
some activity in bone marrow in vivo after 2 h in pilot
experiments (data not shown). Co-treatment with carfil-
zomib and LU-102 was tolerated without weight loss or
overt clinical toxicity. We observed a significant reduction
in mean tumor size in mice treated with carfilzomib+LU-
102, compared to mice treated with either single agent:
mean difference in tumor volume between carfilzomib-
treated versus carfilzomib+LU-102 treated mice 353 mm3
(95%CI: 130-576 mm3; P=0.008); difference for LU-102
treated versus carfilzomib+LU102 treated 432 (95%CI: 46-
817 mm3; P=0.03) (Table 2). This translated into a survival
advantage of mice treated with the carfilzomib+LU-102
combination relative to mice undergoing either monother-
apy (median survival 48 days for combination treatment
versus 38 and 39.5 for LU-102 or carfilzomib mono-thera-
py, respectively; P=0.02 and 0.009 (Figure 6).  Co-treat-
ment with bortezomib (1 mg/kg) and LU-102 resulted in
hemorrhagic enteritis in the majority of mice and was,
therefore, not feasible at the indicated doses (data not
shown). We conclude that co-treatment with LU-102 is fea-
sible and increases the antimyeloma activity of carfil-
zomib in vivo.
Discussion
Bortezomib-resistant myeloma cells contain increased
proteolytic processing capacity, including upregulation of
the β2 proteasome activity not targeted by bortezomib.20
We hypothesized that β2 proteasome activity contributes
to bortezomib resistance and may, therefore, represent a
rational target for the treatment of proteasome inhibitor-
resistant myeloma.
We here describe the effect of LU-102, the first β2/β2i-
selective proteasome inhibitor available for pre-clinical
studies in myeloma, on bortezomib- and carfilzomib-
resistant myeloma cells. Selective elimination of β2 pro-
teasome activity alone was not sufficient to induce a
meaningful cytotoxic effect in bortezomib- or carfilzomib-
resistant myeloma cells. However, the combination of LU-
102 with bortezomib or carfilzomib was highly potent to
overcome bortezomib- or carfilzomib-resistance. This
was observed not only in a proteasome inhibitor-adapted
myeloma cell line model that mirrors several of the biolog-
ical features of bortezomib resistance in patients, but also
in a model of bone marrow stroma-mediated proteasome
inhibitor resistance, and in primary malignant plasma cell
samples from bortezomib-resistant patients.  Based on our
results, we suggest the following mechanism: co-inhibi-
tion of the β2/β2i proteasome activity during treatment
with the β5-targeted drugs bortezomib or carfilzomib
results in more effective accumulation of proteasome sub-
strate proteins due to reduced levels of residual total pro-
teasome activity, as well as due to prolonged proteasome
inhibition. The accumulation of proteasome sub-strate
protein triggers the UPR, and in particular its major regu-
latory axis, IRE-1a/XBP-1. Downregulation of IRE1-
a/XBP1 is known to mediate bortezomib-resistance of
myeloma cells19 and high XBP-1 is a biomarker for borte-
zomib sensitivity in the clinic.9 The synergistic induction
of the UPR, and in particular IRE-1a, by LU-102 in combi-
nation with bortezomib/carfilzomib results in increased
sensitivity of myeloma cells to UPR-associated apoptosis
and myeloma cell death. This can in part be rescued when
protein biosynthesis and hence the level of ER stress after
additional inhibition of β2/β2i is mitigated by cyclohex-
imide, an inhibitor of protein translation.
Recent data suggest that bortezomib resistance in
myeloma is an adaptive process in which the myeloma
cell population adjusts the homeostasis of its protein
biosynthesis apparatus to the selective pressure of protea-
some inhibition.19 This is achieved by decreased activity of
the IRE-1a/XBP-1 regulatory axis of the UPR, which
results in a more immature differentiation stage of myelo-
ma cells and a reduction of the protein biosynthesis
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Figure 6. Effect of the combination of carfilzomib with LU-102 on
myeloma bearing mice in vivo MM1.S cells were injected into SCID
mice (3x106 cells in 100 μL/mouse). Twice-weekly intraperitoneal
treatments with LU-102 (30 mg/kg) combined with intravenous
carfilzomib (CFZ) was performed as indicated. Mice were euthanized
when tumors reached 3000mm3.   
machinery of the ER. We currently lack appropriate ani-
mal models for bortezomib-resistant myeloma that reflect
this biology in vivo. However, the essential features of this
“adaptive bortezomib resistance” in myeloma patients
outlined by Leung-Hagesteijn19 are mirrored well in the in
vitro model of bortezomib/carfilzomib-adapted myeloma
cells that we used here (selective pressure by a proteasome
inhibitor, lack of mutations in the inhibitor-binding active
site, decreased protein biosynthesis rate of resistant cells,
decreased XBP-1 expression of resistant cells). The lack of
mutations that would prevent effective binding of the
drugs in the proteasome inhibitor binding pockets of our
bortezomib/carfilzomib-adapted cells was verified by
sequencing, but can also be deduced from Figure 4A,
where more than 90% inhibition of the respective base-
line bortezomib or carfilzomib-reactive proteasome activ-
ities was achieved by either bortezomib or carfilzomib in
the bortezomib/carfilzomib resistant adapted cells. This is
also in agreement with the lack of evidence for borte-
zomib resistance-conferring proteasome gene mutations
in clinical samples.18,31 It remains to be assessed whether
myeloma with acquired bortezomib-resistance is similarly
characterized not only by a reduced load of protein
biosynthesis, but also by an increased β2 proteasome
activity in vivo, as suggested by the in vitro model.
The therapeutic potential of targeting the β2/β2i protea-
some activity as an addition to β5-targeted drugs is support-
ed by pre-clinical as well as by clinical data: in most myelo-
ma cell lines, the cytotoxicity of proteasome inhibitors does
not correlate with the degree of inhibition of the chy-
motryptic activity, but with loss of subunit selectivity and
the onset of inhibition of the tryptic or caspase-like sites.21
Carfilzomib has a particularly high clinical activity against
relapsed and refractory myeloma when delivered at an
escalated 20/56 mg/m2 dose, which results in significant co-
inhibition of β2i activity in vivo (also in agreement with
Figure 1A32). Indeed, our data demonstrate that the
antimyleoma activity of carfilzomib in vivo can be increased
by additional β2-inhibition with LU-102. It has been shown
that combination of two β5-targeted proteasome inhibitors
enhance the anti-myeloma activity of each, supporting the
concept of combining proteasome inhibiting drugs.33
LU-102 is the first β2-selective proteasome inhibitor
available to test a novel treatment concept to overcome
bortezomib/carfilzomib resistance via simulatenous inhi-
bition of the β2 proteasome subunit. However, LU-102
still has important limitations for potential clinical use,
including its micromolar activity and poor tolerability of
the vinylsulfone-type inhibitor in combination with borte-
zomib in the murine model. Replacing the reactive group
by an epoxyketone, similar to carfilzomib, and fine-tuning
the substituents in particular in the P1 and P3 positions
with additional non-natural aminoacids with pKa cover-
ing the 5.5-9.0 range are predicted to improve activity,
selectivity and cell permeability, and are underway to
yield improved β2-selective candidate compounds
towards further pre-clinical development of this concept.
In summary, our results demonstrate that the combina-
tion of bortezomib or carfilzomib with LU-102, a novel
irreversible inhibitor selective for the β2/β2i proteasome
subunits, induces superior proteasome inhibition and UPR
activation compared to bortezomib or carfilzomib alone.
This results in highly synergistic induction of proteotoxic
death in bortezomib/carfilzomib-resistant myeloma cells.
The combination of β5-targeting proteasome inhibitors
with β2-selective proteasome inhibition may in particular
offer treatment options for patients with
bortezomib/carfilzomib resistant myeloma, a growing
patient group with poor therapeutic options. Based on
their target profile, β2-selective proteasome inhibitors
may be potentially applied also to increase the antimyelo-
ma activity of delanzomib, ixazomib and oprozomib in
the future.
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